Skip to Content
Merck
All Photos(1)

Documents

I9890

Sigma-Aldrich

m-Iodobenzylguanidine hemisulfate salt

≥98% (HPLC and TLC)

Synonym(s):

MIBG

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
C8H10IN3 · 1/2H2SO4
CAS Number:
87862-25-7
Molecular Weight:
324.13
MDL number:
MFCD00151189
UNSPSC Code:
12352200
PubChem Substance ID:
24278499
NACRES:
NA.77

Quality Level

200

Assay

≥98% (HPLC and TLC)

impurities

<0.5% Free iodobenzylamine

storage temp.

2-8°C

SMILES string

OS(O)(=O)=O.NC(=N)NCc1cccc(I)c1.NC(=N)NCc2cccc(I)c2

InChI

1S/2C8H10IN3.H2O4S/c2*9-7-3-1-2-6(4-7)5-12-8(10)11;1-5(2,3)4/h2*1-4H,5H2,(H4,10,11,12);(H2,1,2,3,4)

InChI key

XNACDNPGABUBFR-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Antitumor agent which inhibits ADP ribosylation.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Steven G DuBois et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 21(12), 2715-2721 (2015-02-20)
(131)I-metaiodobenzylguanidine (MIBG) is a radiopharmaceutical with activity in neuroblastoma. Vorinostat is a histone deacetylase inhibitor that has radiosensitizing properties. The goal of this phase I study was to determine the MTDs of vorinostat and MIBG in combination. Patients ≤ 30
Adrien Lebasnier et al.
European journal of nuclear medicine and molecular imaging, 42(7), 1043-1051 (2015-01-30)
The aim of this study was to determine the potential diagnostic value of regional myocardial adrenergic (123)I-metaiodobenzylguanidine (MIBG) single photon emission computed tomography (SPECT) imaging to identify patients with Lewy body diseases (LBD+). Sixty-four consecutive patients who underwent cardiac (123)I-MIBG
L A Smets et al.
Cancer chemotherapy and pharmacology, 21(1), 9-13 (1988-01-01)
Meta-iodo-benzylguanidine (MIBG) is an analogue of the neurotransmitter norepinephrine. In its radioiodinated form, MIBG is clinically used as a tumor-targeted radiopharmaceutical in the diagnosis and treatment of adrenergic tumors. The potential cytotoxicity of the unlabeled drug was tested. MIBG appeared
Sylvie Slaets et al.
International journal of geriatric psychiatry, 30(8), 864-869 (2014-11-05)
Iodine-123 metaiodobenzylguanidine (MIBG) cardiac scintigraphy has shown the potential to discriminate dementia with Lewy bodies (DLB) from Alzheimer's disease (AD). However, these studies did not reflect clinical practice, as patients with ischemic heart disease, heart failure, diabetes mellitus, arterial hypertension
Yunlong Zan et al.
Molecular imaging, 14, 373-384 (2015-07-15)
The objective of this work was to evaluate the sympathetic nervous system and structure remodeling during the progression of heart failure in a rodent model using dynamic cardiac single-photon emission computed tomography (SPECT). The spontaneously hypertensive rat (SHR) model was
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service